Goggi, J, Haslop, A, Ramasamy, B, et al. Identifying nonsmall‐cell lung tumours bearing the T790M EGFR TKI resistance mutation using PET imaging. J Label Compd Radiopharm. 2019; 62: 596– 603. https://doi.org/10.1002/jlcr.3771
Abstract:
Specific mutations significantly affect response to epidermal growth factor tyrosine kinase inhibitor (EGFR‐TKI) treatment in lung cancer patients. Identifying patients with these mutations remains a major clinical challenge. EGFR T790M mutation, which conveys resistance to in the present study, [18F]FEWZ was assessed in vitro to determine efficacy relative to the starting compound and in vivo to measure the biodistribution and specificity of binding to EGFR wild‐type, L858R and T790M bearing tumours. [18F]FEWZ is the first evidence of a radiolabeled third generation anilinopyrimidine‐derived tyrosine kinase inhibitor targeting T790M mutation bearing tumours in vivo.
License type:
PublisherCopyrights
Funding Info:
This work was supported by funding from the Singapore Bioimaging Consortium, A*STAR.
Description:
This is the pre-peer reviewed version of the following article: Goggi, J, Haslop, A, Ramasamy, B, et al. Identifying nonsmall‐cell lung tumours bearing the T790M EGFR TKI resistance mutation using PET imaging. J Label Compd Radiopharm. 2019; 62: 596– 603. https://doi.org/10.1002/jlcr.3771, which has been published in final form at https://doi.org/10.1002/jlcr.3771. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.